7F
7F0.F Fulgent Genetics Inc
- Market cap
- EUR 643M
- P/E
- -
- P/B
- 0.75x
- ROE
- -9.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 7F0.F undervalued?
Graham numberThe Graham number of Fulgent Genetics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fulgent Genetics Inc fundamental analysis
No fundamental analysis for Fulgent Genetics Inc yet.
Fulgent Genetics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing service…
Full company profileFulgent Genetics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fulgent Genetics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18.3M | 18.7M | 21.4M | 32.5M | 422M | 993M | 619M | 289M | 283M | 323M | 329M |
| Gross Profit | 11.6M | 10.2M | 10.7M | 18.4M | 332M | 777M | 367M | 104M | 107M | 131M | 105M |
| Operating Income | 918K | -3.48M | -5.07M | -428K | 290M | 676M | 182M | -75.3M | -73.9M | -91.1M | -121M |
| EBITDA | - | -1.75M | -2.91M | 1.68M | 293M | 678M | 188M | -147M | -49.0M | -45.8M | -65.5M |
| Net Income | -5.35M | -2.51M | -5.61M | -411K | 214M | 507M | 143M | -168M | -42.7M | -60.5M | -90.0M |
| EPS | - | -0.14 | -0.31 | -0.02 | 7.61 | 17 | 4.87 | -5.59 | -1.38 | -1.95 | -3.24 |
| Balance Sheet | |||||||||||
| Total Assets | 58.0M | 57.2M | 53.9M | 88.8M | 700M | 1.28B | 1.39B | 1.24B | 1.22B | 1.21B | 1.08B |
| Total Liabilities | 3.56M | 3.01M | 2.75M | 5.98M | 131M | 113M | 116M | 102M | 90.8M | 107M | 94.2M |
| Shareholders' Equity | 54.5M | 54.2M | 51.2M | 82.8M | 569M | 1.17B | 1.27B | 1.14B | 1.13B | 1.11B | 990M |
| Cash & Short-term Investments | 7.90M | 6.49M | 6.74M | 12.0M | 87.4M | 165M | 79.5M | 97.5M | 55.1M | 50.2M | 86.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.41M | 1.33M | -675K | 5.52M | 141M | 539M | 254M | 27.0M | 21.1M | -102M | 123M |
| Capital Expenditure | 3.79M | 5.36M | 2.83M | 1.18M | 35.1M | 23.8M | 18.8M | 22.2M | 40.3M | 22.6M | 14.5M |
| Free Cash Flow | - | -4.03M | -3.51M | 4.20M | 104M | 515M | 235M | 4.80M | -19.3M | -124M | 109M |
| Ratios | |||||||||||
| ROE | -9.8% | -4.6% | -11.0% | -0.5% | 37.6% | 43.5% | 11.3% | -14.8% | -3.8% | -5.4% | -9.1% |
| ROA | -9.2% | -4.4% | -10.4% | -0.5% | 30.6% | 39.7% | 10.3% | -13.6% | -3.5% | -5.0% | -8.3% |
| Net Profit Margin | -29.3% | -13.4% | -26.3% | -1.3% | 50.8% | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% | -27.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Fulgent Genetics Inc dividends
Fulgent Genetics Inc has not paid dividends in the last 9 fiscal years.
Who owns Fulgent Genetics Inc
- Insiders 37.14%
- Institutions 56.67%
- Public & others 6.19%
- Shares outstanding 27.9M
- Free float 17.1M
Fulgent Genetics Inc company profile
- Company name
- Fulgent Genetics Inc
- Ticker
- 7F0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,315
- Fiscal year end
- December
- Address
- 4399 Santa Anita Avenue, El Monte, CA, United States, 91731
- Phone
- 626 350 0537
- Website
- fulgentgenetics.com
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Fulgent Genetics Inc management
10- Mr. Ming HsiehChairman & CEO · born 1956
- Mr. Jian XieCOO & President · born 1966
- Mr. Paul Kim CPAChief Financial Officer · born 1967
- Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D.Chief Scientific Officer & Lab Director · born 1967
- Ms. Natalie Prescott CIPM, CIPPGeneral Counsel & Chief Privacy Officer
- Ms. Doreen NgVice President of Operations & Compliance
- Mr. Jakub SramVice President of Business Development & Sales
- Ms. Ellen TsuiVice President of Human Resources
- Mr. Brandon PerthuisChief Commercial Officer
- Mr. Elias NyankojoChief Information Security Officer